Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalind Rowland

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
The Journal of Infectious Diseases|January 26, 2012
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vectorGeraldine A O'Hara, Christopher J A Duncan, Katie J Ewer, et al.
Nature Communications|November 29, 2013
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisationKatie J Ewer, Geraldine A O'Hara, Christopher J A Duncan, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
The Journal of Infectious Diseases|January 26, 2012
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vectorGeraldine A O'Hara, Christopher J A Duncan, Katie J Ewer, et al.
Nature Communications|November 29, 2013
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisationKatie J Ewer, Geraldine A O'Hara, Christopher J A Duncan, et al.
Pageof 2